571 related articles for article (PubMed ID: 23241032)
1. When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist?
Bangalore S; Kumar S; Messerli FH
Congest Heart Fail; 2013; 19(3):107-15. PubMed ID: 23241032
[TBL] [Abstract][Full Text] [Related]
2. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
4. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
Xie W; Zheng F; Song X; Zhong B; Yan L
Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
6. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.
Meune C; Wahbi K; Duboc D; Weber S
J Cardiovasc Pharmacol Ther; 2011; 16(3-4):368-75. PubMed ID: 21193681
[TBL] [Abstract][Full Text] [Related]
8. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
10. Aldosterone antagonists for preventing the progression of chronic kidney disease.
Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
[TBL] [Abstract][Full Text] [Related]
11. The renin-angiotensin-aldosterone system and heart failure.
Sayer G; Bhat G
Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
[TBL] [Abstract][Full Text] [Related]
12. Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock.
van Diepen S; Reynolds HR; Stebbins A; Lopes RD; Džavík V; Ruzyllo W; Geppert A; Widimsky P; Ohman EM; Parrillo JE; Dauerman HL; Baran DA; Hochman JS; Alexander JH
Crit Care Med; 2014 Feb; 42(2):281-8. PubMed ID: 23982033
[TBL] [Abstract][Full Text] [Related]
13. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
[TBL] [Abstract][Full Text] [Related]
14. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
Catalá-López F; Macías Saint-Gerons D; González-Bermejo D; Rosano GM; Davis BR; Ridao M; Zaragoza A; Montero-Corominas D; Tobías A; de la Fuente-Honrubia C; Tabarés-Seisdedos R; Hutton B
PLoS Med; 2016 Mar; 13(3):e1001971. PubMed ID: 26954482
[TBL] [Abstract][Full Text] [Related]
16. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C; Pöss J; Böhm M
Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
19. Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials.
Hansen MR; Hróbjartsson A; Videbæk L; Ennis ZN; Pareek M; Paulsen NH; Broe M; Olesen M; Pottegård A; Damkier P; Hallas J
Am J Med; 2020 Jun; 133(6):e280-e289. PubMed ID: 32173347
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]